Series A · Biotech
RegCell raises $44m Series A alongside $22m grant
The platform is designed to avoid gene engineering and broad immunosuppression.
Playground Global led the Series A, with LG Technology Ventures, Alumni Ventures and existing Japanese backers participating.
RegCell plans to advance epigenetic reprogramming toward clinical development, expand its pipeline and Phase 2 work and accelerate its second-generation platform.
The $22m non-dilutive AMED grant is distinct from the $44m Series A. The combined $66m must not be described as one equity round.
Use of funds
Advance epigenetic reprogramming into clinical development
Expand clinical pipeline and Phase 2 studies
Accelerate second-generation platform
Funding history
Series A · This round$44M